Evenamide, as an add-on to antipsychotics, produces long-lasting clinically meaningful benefit and converts treatment-resistant schizophrenia (TRS) patients into a responsive state: 6-month results from an ongoing international randomized study

[P502] Evenamide, as an add-on to antipsychotics, produces long-lasting clinically meaningful benefit and converts treatment-resistant schizophrenia (TRS) patients into a responsive state: 6-month results from an ongoing international randomized study

*Ravi Anand¹, Alessio Turolla², Giovanni Chinellato², Francesca Sansi², Rodolfo Giuliani² (1. Anand Pharma Consulting, 2. Newron Pharmaceuticals SpA)

Keywords:Treatment resistant schizophrenia, long-term treatment, glutamate modulation, add-on treatment, pharmacological intervention

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.